Priti Gupta1, Charles F Hodgman1, Keri L Schadler2, Emily C LaVoy3. 1. Department of Health and Human Performance, The University of Houston, 3875 Holman St., Rm 104 Garrison, Houston, TX, 77204-6015, USA. 2. Department of Pediatrics, MD Anderson Cancer Center, Houston, TX, USA. 3. Department of Health and Human Performance, The University of Houston, 3875 Holman St., Rm 104 Garrison, Houston, TX, 77204-6015, USA. eclavoy@central.uh.edu.
Abstract
INTRODUCTION: Exercise can lower the risk of developing pancreatic cancer and has the potential to improve physical fitness and quality of life in patients with the disease. Yet, the effects of exercise training during pancreatic cancer treatment remain poorly characterized. This hampers the development of evidence-based disease-specific exercise recommendations. PURPOSE: The purpose of this review was to describe and interpret the effect of exercise on physiological, QoL, and cancer-specific outcomes reported in clinical trials among pancreatic cancer patients during treatment. METHODS: We conducted a scoping review of the literature according to the framework proposed by Arksey and O'Malley. Articles published prior to December 2021 were retrieved from PubMed, EMBASE, and Scopus. We only included studies that prescribed structured cardiorespiratory and/or resistance exercise in pancreatic cancer patients undergoing treatment. RESULTS: A total of 662 references were retrieved, of which 24 are included in the review. Twelve articles were randomized controlled trials and 12 were single-arm trials. Overlap in the trials from which data were reported occurred in 16 articles. Moderate intensity exercise was most commonly prescribed, reported feasible for most patients, with potential to enhance physical fitness and QoL. However, exercise adherence and beneficial effects may diminish with disease progression. Limited evidence suggests exercise may benefit cancer-specific outcomes. CONCLUSION: The results of this review indicate that exercise is feasible during pancreatic cancer treatment. Exercise can also improve physical fitness and QoL. However, its beneficial effects may fall with advanced disease and more rigorous research is needed to develop precise exercise protocols for this population.
INTRODUCTION: Exercise can lower the risk of developing pancreatic cancer and has the potential to improve physical fitness and quality of life in patients with the disease. Yet, the effects of exercise training during pancreatic cancer treatment remain poorly characterized. This hampers the development of evidence-based disease-specific exercise recommendations. PURPOSE: The purpose of this review was to describe and interpret the effect of exercise on physiological, QoL, and cancer-specific outcomes reported in clinical trials among pancreatic cancer patients during treatment. METHODS: We conducted a scoping review of the literature according to the framework proposed by Arksey and O'Malley. Articles published prior to December 2021 were retrieved from PubMed, EMBASE, and Scopus. We only included studies that prescribed structured cardiorespiratory and/or resistance exercise in pancreatic cancer patients undergoing treatment. RESULTS: A total of 662 references were retrieved, of which 24 are included in the review. Twelve articles were randomized controlled trials and 12 were single-arm trials. Overlap in the trials from which data were reported occurred in 16 articles. Moderate intensity exercise was most commonly prescribed, reported feasible for most patients, with potential to enhance physical fitness and QoL. However, exercise adherence and beneficial effects may diminish with disease progression. Limited evidence suggests exercise may benefit cancer-specific outcomes. CONCLUSION: The results of this review indicate that exercise is feasible during pancreatic cancer treatment. Exercise can also improve physical fitness and QoL. However, its beneficial effects may fall with advanced disease and more rigorous research is needed to develop precise exercise protocols for this population.
Authors: Michael A O'Rorke; Marie M Cantwell; Chris R Cardwell; Helen G Mulholland; Liam J Murray Journal: Int J Cancer Date: 2010-06-15 Impact factor: 7.396
Authors: Anne McTiernan; Christine M Friedenreich; Peter T Katzmarzyk; Kenneth E Powell; Richard Macko; David Buchner; Linda S Pescatello; Bonny Bloodgood; Bethany Tennant; Alison Vaux-Bjerke; Stephanie M George; Richard P Troiano; Katrina L Piercy Journal: Med Sci Sports Exerc Date: 2019-06 Impact factor: 5.411
Authors: Colleen Doyle; Lawrence H Kushi; Tim Byers; Kerry S Courneya; Wendy Demark-Wahnefried; Barbara Grant; Anne McTiernan; Cheryl L Rock; Cyndi Thompson; Ted Gansler; Kimberly S Andrews Journal: CA Cancer J Clin Date: 2006 Nov-Dec Impact factor: 508.702
Authors: Maria Baimas-George; Michael Watson; Kyle Thompson; Vivek Shastry; David Iannitti; John B Martinie; Erin Baker; Armida Parala-Metz; Dionisios Vrochides Journal: Am Surg Date: 2020-11-10 Impact factor: 0.688
Authors: Hao Luo; Daniel A Galvão; Robert U Newton; Pedro Lopez; Colin Tang; Ciaran M Fairman; Nigel Spry; Dennis R Taaffe Journal: Pancreas Date: 2021-03-01 Impact factor: 3.243
Authors: Naomi M Sell; Julie K Silver; Stephanie Rando; Ashley C Draviam; Daniel Santa Mina; Motaz Qadan Journal: Ann Surg Date: 2020-08 Impact factor: 12.969
Authors: Benjamin Singh; Sandra C Hayes; Rosalind R Spence; Megan L Steele; Guillaume Y Millet; Laurent Gergele Journal: Int J Behav Nutr Phys Act Date: 2020-09-24 Impact factor: 6.457